自体造血干细胞移植治疗首次CR非霍奇金淋巴瘤

目的报告8例首次CR非霍奇金淋巴瘤（NHL）在外周血干细胞移植（PBSCT）支持下接受超大剂量化疗（HDC）的初步经验并评价所用外周血造血干细胞（PBSC）动员方案的动员效果,预处理方案的耐受性以及PBPC回输后造血重建情况。方法 8例NHL经常规化疗获首次完全缓解后,采用大剂量ICE方案（IFO5g/m2、卡铂AUC=7、VP-16500mg/m2）＋G-CSF5μg/（kg.次）作动员方案,经超大剂量化疗方案BEAM（BCNU300mg/m2d1,VP-16200mg/m2d1-4,Ara-C200mg/m2q12hd1-4,Mephlan140mg/m2d4）进行预处理后回输PBSC。结果分别采集到MNC2.7（2.3-4.3）×108/kg,CFU-GM5.0（2.5-9.8）×105/kg和CD34＋细胞2.9（2.1-8.8）×106/kg。回输PBSC后,均获快速重建造血功能,ANC〉0.5×109/L和Pt〉2.0×109/L的时间为10（8～12）d和11（9～18）d。非造血系统毒性较轻。随访至2009年6月底,中位随访时间24（10～46）个月,6例存活,1年生存率100%,3年存活率75%。结论自体外周血干细胞移植支持下超大剂量化疗是治疗首次CR非霍奇金淋巴瘤安全有效的临床手段,值得进一步研究。

Non-Hodgkin's Lymphoma in First Complete Remission Were Treated by Autlogous Hemotopoietic Stem Cells Transplantation

Objective] The purpose of this study was to evaluate the efficacy of mobilization regimen,effectiveness and tolerance of BEAM in first complete remission patients with non-Hodgkin's lymphoma,and hemotopoietic reconstitution.Methods] After confirmed complete remission from conventional chemotherapy,8 patients with primary NHL,were enrolled into this study and treated with BEAM((BCNU 300 mg/m2 d1,VP-16 200 mg/m2 d1-4,Ara-C 200mg/m2 q12 h d1-4,Mephlan 140 mg/m2 d4)),patients were supported by APBSCT.Mobiliza...